Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Lestaurtinib. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NTRK1 known ✓ | P04629 | 10/20 | 1.00 |
| ▸ | FLT3 known ✓ | P36888 | 5/20 | 1.00 |
| ▸ | JAK2 known ✓ | O60674 | 2/20 | 1.00 |
| ▸ | RET known ✓ | P07949 | 2/20 | 1.00 |
| ▸ | NTRK3 known ✓ | Q16288 | 1/20 | 1.00 |
| ▸ | NTRK2 known ✓ | Q16620 | 1/20 | 1.00 |
| ▸ | KDR | P35968 | 9/20 | 1.00 |
| ▸ | PRKCQ | Q04759 | 7/20 | 1.00 |
| ▸ | PRKD3 | O94806 | 5/20 | 1.00 |
| ▸ | PRKCA | P17252 | 5/20 | 1.00 |
| ▸ | PRKCH | P24723 | 5/20 | 1.00 |
| ▸ | PRKCI | P41743 | 5/20 | 1.00 |
| ▸ | PRKCE | Q02156 | 5/20 | 1.00 |
| ▸ | PRKCD | Q05655 | 5/20 | 1.00 |
| ▸ | PRKD1 | Q15139 | 5/20 | 1.00 |
| ▸ | MYLK | Q15746 | 4/20 | 1.00 |
| ▸ | CDK4 | P11802 | 3/20 | 1.00 |
| ▸ | CDK2 | P24941 | 3/20 | 1.00 |
| ▸ | MAP3K11 | Q16584 | 3/20 | 1.00 |
| ▸ | CAMKK2 | Q96RR4 | 3/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Lestaurtinib SCHEMBL16139562 | 1.00 | NTRK1 (1.00) | NTRK1KDRPRKCQFLT3PRKD3 | |
| Lestaurtinib SCHEMBL730955 | 1.00 | NTRK1 (1.00) | NTRK1KDRPRKCQFLT3PRKD3 | |
| Lestaurtinib SCHEMBL1649693 | 1.00 | NTRK1 (1.00) | NTRK1KDRPRKCQFLT3PRKD3 | |
| Lestaurtinib SCHEMBL12228516 | 1.00 | NTRK1 (1.00) | NTRK1KDRPRKCQFLT3PRKD3 | |
| Lestaurtinib SCHEMBL17971367 | 1.00 | NTRK1 (1.00) | NTRK1KDRPRKCQFLT3PRKD3 | |
| Lestaurtinib SCHEMBL17971365 | 1.00 | NTRK1 (1.00) | NTRK1KDRPRKCQFLT3PRKD3 | |
| Lestaurtinib SCHEMBL12963759 | 1.00 | NTRK1 (1.00) | NTRK1KDRPRKCQFLT3PRKD3 | |
| Lestaurtinib SCHEMBL13169434 | 1.00 | NTRK1 (1.00) | NTRK1KDRPRKCQFLT3PRKD3 | |
| Lestaurtinib SCHEMBL30149252 | 0.99 | NTRK1 (0.98) | NTRK1KDRPRKCQFLT3PRKD3 | |
| SCHEMBL14342269 | 0.94 | NTRK1 (0.89) | NTRK1KDRPRKCQFLT3PRKD3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12516321-B2 | RNA interference mediated inhibition of gene expression using short interfering nucleic acids (siNA) | SIRNA THERAPEUTICS, INC. (US) | 2026-01-06 | — | — | US | disclosed |
| WO-2025244963-A1 | ECTEINASCIDIN DERIVATIVES AND METHODS OF USE THEREOF AS ANTITUMOR AGENTS | MERCK SHARP & DOHME LLC (US) | 2025-11-27 | — | — | WO | disclosed |
| EP-4630001-A1 | SUBSTITUTED QUINAZOLINE DERIVATIVES AND METHODS OF USE THEREOF | Merck Sharp & Dohme LLC (US) | 2025-10-15 | — | — | EP | disclosed |
| EP-4608398-A1 | PNU ANTHRACYCLINE DERIVATIVES AND METHODS OF USE THEREOF | Merck Sharp & Dohme LLC (US) | 2025-09-03 | — | — | EP | disclosed |
| WO-2025136841-A1 | SUBSTITUTED ISOQUINOLINE DERIVATIVES AND METHODS OF USE THEREOF | MERCK SHARP & DOHME LLC (US) | 2025-06-26 | — | — | WO | disclosed |
| US-20240287515-A1 | RNA INTERFERENCE MEDIATED INHIBITION OF GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACIDS (SINA) | BANK OF AMERICA, N.A. | 2024-08-29 | — | — | US | disclosed |
| WO-2024123585-A1 | SUBSTITUTED QUINAZOLINE DERIVATIVES AND METHODS OF USE THEREOF | MERCK SHARP & DOHME LLC (US) | 2024-06-13 | — | — | WO | disclosed |
| US-11993602-B2 | PRMT5 inhibitors | MERCK SHARP & DOHME LLC (US) | 2024-05-28 | — | — | US | disclosed |
| WO-2024091894-A1 | PNU ANTHRACYCLINE DERIVATIVES AND METHODS OF USE THEREOF | MERCK SHARP & DOHME LLC (US) | 2024-05-02 | — | — | WO | disclosed |
| US-20230114091-A1 | PRMT5 INHIBITORS | MERCK SHARP & DOHME LLC (US) | 2023-04-13 | — | — | US | disclosed |
| EP-4161522-A1 | PYRAZOLO[4,3-D]PYRIMIDINE DERIVATIVES AND METHODS OF USE THEREOF FOR THE TREATMENT OF CELLULAR PROLIFERATIVE DISORDERS | Merck Sharp & Dohme LLC (US) | 2023-04-12 | — | — | EP | disclosed |
| US-20230104690-A1 | MATRIX METALLOPROTEINASE INHIBITORS (MMPIs) | BRANDON UNIV (CA) | 2023-04-06 | — | — | US | disclosed |
| EP-4076460-A1 | PRMT5 INHIBITORS | Merck Sharp & Dohme LLC (US) | 2022-10-26 | — | — | EP | disclosed |
| EP-4076452-A1 | PRMT5 INHIBITORS | Merck Sharp & Dohme LLC (US) | 2022-10-26 | — | — | EP | disclosed |
| WO-2022198325-A1 | CAMPTOTHECIN (CPT) DERIVATIVE(S) AND METHODS AND USES THEREOF | TRANMER GEOFFREY K G (CA) | 2022-09-29 | — | — | WO | disclosed |
| US-20220195433-A1 | RNA INTERFERENCE MEDIATED INHIBITION OF GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACIDS (SINA) | BANK OF AMERICA, N.A. | 2022-06-23 | — | — | US | disclosed |
| EP-4003523-A1 | ANTI-PD-1/LAG3/TIGIT TRISPECIFIC ANTIBODIES AND ANTI-PD-1/LAG3 BISPECIFIC ANTIBODIES | Merck Sharp & Dohme Corp. (US) | 2022-06-01 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230114091-A1 | PRMT5 INHIBITORS | PRMT5, PRMT1, PRMT3 | NTRK1 4854/4885FLT3 194/4885JAK2 741/4885 |
| US-20230104690-A1 | MATRIX METALLOPROTEINASE INHIBITORS (MMPIs) | MMP11, MMP9, MMP3 | NTRK1 4068/4885FLT3 3906/4885JAK2 3916/4885 |
| US-11993602-B2 | PRMT5 inhibitors | PRMT5, PRMT1, PRMT6 | NTRK1 4843/4885FLT3 382/4885JAK2 618/4885 |
| US-20220195433-A1 | RNA INTERFERENCE MEDIATED INHIBITION OF GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACIDS (SINA) | MAOA, SNRPE, SNRPA | NTRK1 2672/4885FLT3 4648/4885JAK2 867/4885 |
| US-20240287515-A1 | RNA INTERFERENCE MEDIATED INHIBITION OF GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACIDS (SINA) | SNRPE, AGO2, SIN3A | NTRK1 4191/4885FLT3 4560/4885JAK2 1175/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.